RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Santen Pharmaceutical Co Stock

Santen Pharmaceutical Co Net Income 2024

Santen Pharmaceutical Co Net Income

26.63 B JPY

Ticker

4536.T

ISIN

JP3336000009

WKN

864318

In 2024, Santen Pharmaceutical Co's profit amounted to 26.63 B JPY, a -278.09% increase from the -14.96 B JPY profit recorded in the previous year.

The Santen Pharmaceutical Co Net Income history

YEARNET INCOME (undefined JPY)
2027e-
2026e-
2025e-
2024-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-

Santen Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Santen Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Santen Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Santen Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Santen Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Santen Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Santen Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Santen Pharmaceutical Co’s growth potential.

Santen Pharmaceutical Co Revenue, EBIT and net profit per share

DateSanten Pharmaceutical Co RevenueSanten Pharmaceutical Co EBITSanten Pharmaceutical Co Net Income
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
20240 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined

Santen Pharmaceutical Co stock margins

The Santen Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Santen Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Santen Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Santen Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Santen Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Santen Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Santen Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Santen Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Santen Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Santen Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Santen Pharmaceutical Co Margin History

Santen Pharmaceutical Co Gross marginSanten Pharmaceutical Co Profit marginSanten Pharmaceutical Co EBIT marginSanten Pharmaceutical Co Profit margin
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %

Santen Pharmaceutical Co Aktienanalyse

What does Santen Pharmaceutical Co do?

Santen Pharmaceutical Co., Ltd. is a Japanese company specializing in the development and marketing of pharmaceutical products and medical devices. With its headquarters in Osaka, Japan, Santen was founded in October 1890 as Fukuhara Helper's Institute Co., Ltd. Santen started as a small contact lens manufacturer and distributor in 1936, focusing on producing and selling high-quality contact lenses. Over time, the company expanded its product offerings to include ophthalmic products such as eye drops and other medications. In the 1990s, Santen further expanded its business by acquiring other companies and establishing its own research and development department to develop innovative products. Today, Santen is part of a global network of companies specializing in the development and marketing of ophthalmic products. Santen operates in various business areas, including ophthalmology, dermatological and anti-rheumatic medications, as well as medical devices and diagnostic instruments. The company has a presence in over 60 countries worldwide, with branches in the USA, Europe, and Asia. In the field of ophthalmology, Santen offers a wide range of products for the treatment of eye diseases such as glaucoma, dry eye, and allergic conditions. The company has also developed advanced devices for ophthalmology, such as lasers for the treatment of various eye diseases. Santen has also invested in dermatological medicine by offering medications for various skin conditions, including acne, psoriasis, and eczema. Additionally, the company provides medical devices for the diagnosis and monitoring of skin conditions. Specializing in the development of anti-rheumatic medications, Santen offers therapies for conditions such as rheumatoid arthritis and psoriatic arthritis. The company has collaborated with other companies to develop innovations in this field. Santen's business model revolves around developing and marketing innovative products for the healthcare industry. The company aims to provide patients worldwide with access to the best treatments and medical devices. Santen prioritizes research and development, investing a significant portion of its revenue in the development of new products. Overall, Santen offers a wide range of products and services that are in high demand in the healthcare sector. The company has established itself as an innovative provider of top-quality solutions in ophthalmology, dermatology, and rheumatology worldwide. With its strong presence in various countries, Santen continues to invest in the research and introduction of new products that can improve the health and well-being of people. Santen Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Santen Pharmaceutical Co's Profit Margins

The profit margins of Santen Pharmaceutical Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Santen Pharmaceutical Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Santen Pharmaceutical Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Santen Pharmaceutical Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Santen Pharmaceutical Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Santen Pharmaceutical Co stock

How much profit has Santen Pharmaceutical Co made this year?

Santen Pharmaceutical Co has made 26.63 B JPY this year.

How has the profit developed compared to last year?

The profit has increased by -278.09% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Santen Pharmaceutical Co publish its earnings?

Santen Pharmaceutical Co publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Santen Pharmaceutical Co?

The profits of Santen Pharmaceutical Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Santen Pharmaceutical Co?

You can learn more about the earnings of Santen Pharmaceutical Co by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Santen Pharmaceutical Co pay?

Over the past 12 months, Santen Pharmaceutical Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Santen Pharmaceutical Co is expected to pay a dividend of 34.87 JPY.

What is the dividend yield of Santen Pharmaceutical Co?

The current dividend yield of Santen Pharmaceutical Co is .

When does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Santen Pharmaceutical Co?

Santen Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Santen Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 34.87 JPY are expected. This corresponds to a dividend yield of 1.93 %.

In which sector is Santen Pharmaceutical Co located?

Santen Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Santen Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Santen Pharmaceutical Co from 12/1/2024 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Santen Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Santen Pharmaceutical Co in the year 2023?

In the year 2023, Santen Pharmaceutical Co distributed 32 JPY as dividends.

In which currency does Santen Pharmaceutical Co pay out the dividend?

The dividends of Santen Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Santen Pharmaceutical Co

Our stock analysis for Santen Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Santen Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.